Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination

Clinical and Vaccine Immunology

Volumn 20, Issue 8, 2013, Pages 1329-1332

  Scherpenisse, Mirte ^a,b   Schepp, Rutger M ^a   Mollers, Madelief ^a,b   Mooij, Sofie H ^c   Meijer, Chris J L M ^b   Berbers, Guy A M ^a   Van Der Klis, Fiona R M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE L1; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; COMPETITIVE LUMINEX IMMUNOASSAY; CONTROLLED STUDY; GLUTATHIONE S TRANSFERASE L1 BASED MULTIPLEX IMMUNOASSAY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; INTERMETHOD COMPARISON; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; VIRUS LIKE AGENT; VIRUS LIKE PARTICLE MULTIPLEX IMMUNOASSAY;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CLINICAL LABORATORY TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOASSAY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VIROSOMES;

EID: 84880876639     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00153-13     Document Type: Article

References (18)

1. af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J, Lehtinen M, Dillner J. 1998. Stability over time of serum antibody levels to human papillomavirus type 16. J. Infect. Dis. 177:1710-1714.
2. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
3. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. 1994. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. Natl. Cancer Inst. 86:494-499.
4. Dias D, VanDoren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. 2005. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin. Diagn. Lab. Immunol. 12:959-969.
5. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M. 2005. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin. Chem. 51:1845-1853.
6. Sehr P, Rubio I, Pawlita M, Team Muller GSM. 2011. Development and qualification of an automated pseudovirion-based HPV-neutralization assay, abstr O-26.02. Abstr. 27th Int. Papillomavirus Conf., Berlin, Germany.
7. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin. Diagn. Lab. Immunol. 10:108-115.
8. Scherpenisse M, Mollers M, Schepp RM, Boot HJ, de Melker HE, Meijer CJ, Berbers GA, vanderKlis FR. 2012. Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine 30:6686-6693.
9. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. 2007. Prevalence of human papillomavirus antibodies in young female subjects in England. Br. J. Cancer 97:989-991.
10. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. 2009. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003- 2004. J. Infect. Dis. 200:1059-1067.
11. Michael KM, Waterboer T, Sehr P, Rother A, Reidel U, Boeing H, Bravo IG, Schlehofer J, Gartner BC, Pawlita M. 2008. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog. 4:e1000091. doi:10.1371/journal.ppat.1000091.
12. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. 2009. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth. J. Med. 67:301-308.
13. Mooij SH, van der Klis F, van der Sande MAB, Schepp RM, Speksnijder AGCL, Bogaards JA, de Melker HE, vanEeden A, deVries HJC, Schim vanderLoeff MF. 2012. Seroprevalence and determinants of high risk HPV types in HIV-infected and HIV-negative men who have sex with men, abstr FC 3-12. Abstr. Eurogin 2012.
14. Mollers M, Scherpenisse M, van der Klis FR, King AJ, vanRossum TG, vanLogchem EM, Feltkamp MC, Meijer CJ, Snijders PJ, Boot HJ, de Melker HE. 2012. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol. 36:519 -524.
15. Kramer M, Mollema L, Smits G, Boot H, deMelker H, vanderKlis F. 2010. Age-specific HPV seroprevalence among young females in The Netherlands. Sex. Transm. Infect. 86:494-499.
16. Rossi JL, Gissmann L, Jansen K, Muller M. 2000. Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae. Hum. Gene Ther. 11:1165-1176.
17. Michael KM, Waterboer T, Pfister H, Gariglio M, Majewski S, Favre M, Pawlita M. 2010. Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. J. Invest. Dermatol. 130:841-848.
18. Waterboer T, Sehr P, Pawlita M. 2006. Suppression of nonspecific binding in serological Luminex assays. J. Immunol. Methods 309:200-204.